Looking to relocate? Buy a second house? NH Lakes Region Real Estate Agencies are right here!
New Hampshire Lakes Region Real Estate – Find your trusted real estate agent right here and relocate to New England's favorite vacation destination!
NH Lakes Region Real Estate offers you a vast array of choices…looking for lots of acreage? Or is an Island more to your liking?
Buying a home in the Lakes Region is fun when you're working with the right people! Our New Hampshire real estate experts can find the property you've been dreaming of and within your budget. Whether its a lakeside cabin, a luxury estate or anywhere in between the real estate experts of the New Hampshire Lakes region will find you the perfect property for your families needs. Move here soon – it's the ultimate New England getaway!
Full Service Luxury Real Estate Team serving the Lakes Region's Winnipesaukee area. #1 in volume sold. View all Lakes Region properties at www.adamdow.com. We can match your needs and lifestyle with one of the diverse towns around the lake. Each town has its own character and charm, whether it's Wolfeboro's downtown, Alton's location, Gilford's prestigious Governor's Island, Laconia's amenities, Center Harbor's charm, Meredith's great restaurants, Moultonborough's unbelievable properties or Tuftonboro's low taxes- each town brings to the table a unique lifestyle. Start your Lakes Region real estate search right here.
Berkshire Hathaway Home Services Verani Realty has been serving the real estate needs in the communities of New Hampshire and Northern Massachusetts since 1967. We have a reputation for innovation and exemplary customer service.
Bonnie is a Lakes Region Real Estate professional who shows listings and properties in the Carroll County real estate market (Albany, Bartlett, Conway, Effingham, Freedom, Jackson, Madison, North Conway, Ossipee, Sandwich, Tamworth, Tuftonboro, Wakefield and Wolfeboro). Specializing in single and multi-family homes, condos, ski homes, waterfront and/or water access properties on Lake Winnipesaukee, Lake Ossipee and all 7 lakes.
We provide professional services in and around the New Hampshire Lakes Region to Buyers and Sellers of Real Estate. New Hampshire's Lakes Region is a wonderful place to live or enjoy a second vacation home or investment property. The Cisneros Realty Group works with local, out of state and international Buyers and Sellers. To us it's more than just facilitating buying or selling a home. It's about our clients lives, their families, careers and financial position. The Cisneros Realty Group is ready to assist you at a moment's notice. Call us … You'll be happy you did! Start your home sale or purchase by calling us now at 603-273-6160.
It's a buyers market, get a buyers broker. No additional fees. We Work for you, not the seller. Waterfront, Residential, Acreage, Vacation Homes, Islands & Commercial Real Estate.
Costantino Real Estate specializes in residential and land sales in the Ossipee Lake area. This includes the towns of Ossipee, Freedom, Effingham, Wolfeboro, Wakefield and other area towns. You can be confident that we have the inside scoop on all the best properties in the Lakes Region. If you are preparing to buy or list your home, whether it's a vacation home or primary residence, you can trust that we have the best resources to help you.
Our Meredith Associates are industry leaders in the marketing and sale of distinctive properties throughout New Hampshire's Lakes Region. Many of them are graduates of The Institute for Luxury Home Marketing. At Four Seasons Sotheby's International Realty you will discover exceptional properties on and off the water. If you're looking for that classic 1920's lake cottage on Winnipesaukee, or an exquisite Adirondack Style home on Squam Lake, you've come to the right place.
Lakes Region Real Estate-We are a small business that has been in the Lakes Region for 30+ years, with 100 years of experience between our agents. We are an independent Real Estate Shop, with the people and the experience to help you buy, sell or build your Lakes Region real estate dream. We pride ourselves in our personable nature and getting to know our customers well.
Powered by Keller Williams, Lake Life Realty is a close-knit, united team of young, driven entrepreneurial agents who move with the constant evolving trends of the real estate market. If you are looking to buy or sell a luxury home, second home, or are a first-time home buyer, we deliver the same genuine service to all. We are buying and selling specialists and together we all love what we do and love the area in which we work.
We are your #LakeLifeLocals for the Lakes Region of NH.
Squam River Landing a thoughtfully planned, carefully crafted residential community of new, energy-efficient homes overlooking the Squam Lakes.


If you have actually simply discovered out that you have tinnitus (buzzing in the ears), it's essential for you to recognize that no one. It has to 'live with it' or 'deal with it' like what medical professionals generally inform their tinnitus clients. It's due to the fact that you can get rid of tinnitus if you recognize how to, also though no sure-fire clinical therapy for tinnitus is readily available presently. People that deal with this sort of tinnitus are those with persistent sinus problems, rhinitis and allergic reactions.
Cochlear damages make up as much as 85% of calling ears amongst tinnitus victims. Tinnitus as a result of cochlear damages is generally sound damages, a repercussion of constant direct exposure to ear-deafening sounds, such as MP3 gamers (e.g. iPod), performances, loud stereos. And commercial sound, a sudden high degree of sound (e.g. surges). Loud sounds hinder your hearing systems by harming your cochlea. Because of this, tinnitus establishes; in major situations, there might also be listening to lose. The problem might be short-term or long-term.
Cochlear damages might also be brought on by various another occurrence, consisting of ear wax elimination, ear infection, ear or nasal flow surgical treatment, an extreme impact to the head, and head surgical treatment. The individual does not need to subject to loud sounds to establish sounding ears in this instance. If this is the root cause of your tinnitus, you need to after that find out how to handle or lower anxiety to buy ring ease ensure that your tinnitus signs and symptoms can be lowered.
Tension is the source of calling ears in 1 out of 10 tinnitus patients, making it the 2nd most typical reason for the hearing problem. This kind of tinnitus entails failure in the feature of specific integral parts in the mind. Hypothalamus is just one of them. If you are constantly under anxiety, you'll likely to obtain constant episodes of calling ears that are really loud. This is due to the fact that the hypothalamus is seriously influenced by lasting anxiety. And quits generating particular crucial chemicals that your body requires to operate generally.


text:
Rwandan researchers are finally being centred in scholarship about their own country
It is widely known that African researchers are dramatically underrepresented in academic journals. But it's still astonishing to see this reality starkly represented in numbers.
For the past eight years we have run the Research, Policy and Higher Education (RPHE) programme, a research and peer-support scheme with Rwandan scholars, through the Aegis Trust. As part of our work, we've analysed 12 leading journals in disciplines relevant to our researcher cohort. We found that from 1994 until 2019, of the 398 articles focusing on Rwanda that appeared in these journals, only 13 were authored or co-authored by Rwandan scholars. That's just 3.3%. This amounts to 25 years of post-genocide literature almost entirely devoid of Rwandan voices.
In 2019, the flagship area studies journal African Affairs published its first-ever article by a Rwandan. The author, Assumpta Mugiraneza (writing with Benjamin Chemouni) is supported by the RPHE programme. Four of the journals we examined – Journal of Modern African Studies, Journal of Conflict and Security Law, Journal of Peace Research, and Conflict, Security and Development – regularly publish articles on Rwanda. But they are yet to publish a single Rwandan writing on their country.
What explains this level of exclusion? One factor is prejudice on the part of journal editors and peer reviewers, which Rwandan colleagues have encountered for years. It was the need to overcome systemic biases and to amplify the voices of Rwandan scholars in global academic and policy debates that led us to establish the RPHE programme in 2014.
Since we launched, experienced Rwandan and non-Rwandan researchers have worked closely with 44 Rwandan authors selected through four competitive calls that generated more than 400 research proposals. The programme has also organised regular theory, methods, writing and publishing workshops for hundreds of participants in Kigali, supporting the wider Rwandan research community.
It is starting to bear fruit.
A body of scholarly work
Our website, the Genocide Research Hub, has just posted the 21 peer-reviewed journal articles and book chapters that have so far emerged from the programme. It is a rigorous process to reach this point. The authors first produced working papers and policy briefs. These were honed through discussions with their programme colleagues and at public events in Kigali and London. Only then were they submitted to peer-reviewed journals. Over the next year, these working papers will generate a further tranche of academic publications.
Collectively, these pieces represent an important body of scholarly work on various themes. These include ethnicity, indigeneity, migration, citizenship, gender relations and language politics. Authors also delve into debates over younger generations' inherited responsibility for the 1994 genocide against the Tutsi.
The publications highlight the impressive research being conducted by Rwandan authors, who for too long have been sidelined in debates about Rwanda and other conflict-affected societies.
Numerous barriers
Rwandan authors face numerous barriers. Some are domestic and widely acknowledged. The country aims to become a regional high-tech hub. So, the Rwandan government emphasises science, technology, engineering and maths subjects. This has led to the chronic under-funding of the social sciences.
Like their colleagues across East Africa, Rwandan academics' enormous teaching and administrative loads leave little space for research and writing.
Less recognised, however, are the power dynamics in global academic and policy circles. International journal editors, peer reviewers and research funders routinely exclude Rwandan voices. This is driven by a pervasive view that Rwandan authors based in Rwanda cannot produce independent and rigorous research in such a repressive political environment.
These structural biases need to be systematically addressed if institutions and publications based in the global north are serious about the "decolonising knowledge" agenda.
The significance of the academic publications produced through the RPHE programme, though, is not simply that they were written by Rwandans. Crucially, these authors have begun to reorient the substance of scholarly debates about Rwanda and broader peace and conflict issues.
Our calls for proposals asked Rwandan researchers to independently determine the themes and methods of their research, reflecting their deep knowledge of the political, social, cultural, historical and linguistic context. By doing so, they've introduced new themes, angles and insights that greatly enrich the academic literature.
New insights
To take one example, two journal articles by Richard Ntakirutimana – a member of the Rwandan Batwa community – highlight the challenges the Batwa have faced since the Rwandan government placed them under its "Historically Marginalised Peoples" banner in 2007. This category includes guaranteed parliamentary representation for women, people with disabilities, Muslims and the Batwa. But it conflates Batwa concerns with those of other marginalised communities in Rwanda.
Many Batwa are highly wary of researchers. But Ntakirutimana was able to conduct extensive interviews with members of the community near the forests bordering Uganda and the Democratic Republic of Congo. His respondents roundly criticised the "Historically Marginalised Peoples" framework. They demanded government policies tailored more specifically to the plight of the Batwa.
Researchers explore perspectives beyond the capital city, Kigali, giving voice to various Rwandan communities' experiences.
When Ntakirutimana presented his research at an RPHE conference in Kigali, his findings generated vociferous push-back from Rwandan policymakers. His work, and that of other authors from the programme who have presented at public events, challenges a widespread perception of Rwanda as a closed political system in which independent research and public debate on politically sensitive topics are almost impossible.
The RPHE's conferences bring together scholars, journalists and policymakers to discuss research and scholarship about Rwanda.
Aegis Trust/Flickr
Meanwhile, across a wide range of topics and disciplines, the articles published by other RPHE researchers explore an overarching theme largely ignored by non-Rwandan authors: the prevalence of intra-family and inter-generational conflicts since 1994.
These researchers focus on genocidal legacies and the impact of post-genocide social transformation in intimate family spaces, which are difficult for non-Rwandan researchers to access. Their work thus provides vital perspectives on less visible features of Rwandan society.
A gradual shift
The highly talented Rwandan social science research community is beginning to gain the global platform it deserves. This shift is vital for Rwandan researchers. It benefits others, too, by producing fresh insights and challenging the structures that for years stymied these critical voices. More initiatives of this kind are essential if calls to decolonise knowledge are to become more than comforting blandishments.
Our new parliament will have record numbers of women – will this finally make it a safe place to work?
Treasurer Jim Chalmers on the 'spiky' parts of Australia's inflation problem

redpajama_set_name: RedPajamaCommonCrawl


text:
Home » Wireless faces possible change in tax code depreciation
Wireless faces possible change in tax code depreciation
Silva, Jeffrey
RCR Wireless News;10/2/2000, Vol. 19 Issue 40, p14
Focuses on a legislation in the U.S. which is intended to reduce the depreciation life of wireless network equipment. Implication of the bill on wireless telecommunication equipment; Claim of the wireless industry on the classification of technological equipment; Status of the lobbying efforts of the wireless industry on taxes.
Court Decision Sparks Questions About Auction Timing. Vaughan, Allyson // Wireless Week;10/30/2000, Vol. 6 Issue 44, p46
Discusses the issue over the decision of a United States court that allowed General Wireless Inc. to retain spectrum licenses, but could not pay for, in a 1996 C-Block auction. Background on General Wireless case; Factor for the possible delay of the re-auction of spectrum on December 12, 2000....
Voice A 'Killer App' For E911. Stolz, Pascal // Wireless Week;12/18/2000, Vol. 6 Issue 50, p73
Focuses on the mandate of the United States Federal Communications Commission which requires wireless carriers to deploy location technologies with a certain level of accuracy. Challenges facing carriers in the implementation of the technology; Significance of voice-recognition technology;...
FCC wireless proposal endorsed. // Automatic I.D. News;Oct96, Vol. 10 Issue 11, p12
Reports on the Wireless LAN Alliance's endorsement of the Federal Communications Commission's proposal to allocate the 350 megahertz frequency spectrum for use by unlicensed wireless data communications devices.
CPP Issues Fracture Industry. Albright, Peggy // Wireless Week;10/18/99, Vol. 5 Issue 42, p30
Reports that wireless telecommunication carriers and special interest groups will submit comments on calling party pays to the United States Federal Communications Commission. Disagreements between PCIA and CTIA; Reactions from the California Public Utilities Commission.
Four Years And Running. Lockwood, Judith // Wireless Week;02/14/2000, Vol. 6 Issue 7, p4
Comments on the United States 1996 Telecommunications Act. Impact of the law to wireless business and telecommunications industry; Factors affecting the usage of wireless communication systems.
3G Deliberations Enter Final Stage. Albright, Peggy // Wireless Week;02/28/2000, Vol. 6 Issue 9, p85
Focuses on policies on radio frequency bands for third generation wireless telecommunication in the United States. Overview of the agreement on radio frequency bands; Information on a conference sponsored by the Organization of American States' Inter-American Telecommunication Commission;...
Push Off Or Push Forward? Cox, Dave // Wireless Week;07/17/2000, Vol. 6 Issue 29, p57
Presents an opinion on the deadline set by the Federal Communications Commission on the implementation of local number portability (LNP) by wireless carriers for November 2002. Statistics on wireless calls; Forecasted LNP queries that will generate transactions; Details on the SCP-LNP approach.
Spectrum Futures For Sale? Vaughan, Allyson // Wireless Week;11/13/2000, Vol. 6 Issue 46, p1
Reports on the proposal of the United States Federal Communications Commission (FCC) to lease wireless communication spectrum temporarily during a special event and to sell the spectrum on the open market. Reasons behind the scarcity of spectrum; Reasons behind the FCC proposal; Factors...
California Debates Talking Drivers. Albright, Peggy // Wireless Week;03/12/2001, Vol. 7 Issue 11, p29
Focuses on the submission of a bill that ban talking while driving unless the driver is using a hands-free device in California. Stance of Verizon Wireless; Reaction from analysts.
The Price Of Liberty. Menezes, Bill // Wireless Week;11/5/2001, Vol. 7 Issue 45, p4
Comments on the New York's statewide ban on the use of handheld wireless telephones while driving, which took effect in October 2001. Criticisms against the state's lawmakers; Action taken by service providers and industry groups on the matter; Recommendations.
History of Extinctions and Endangered Species Policies
An Overview of Sexual Education in Schools
Sex Education in Schools Today
An Overview of Key Terms and Definitions of Globalization
Economic Stimulus Facts
An Overview of Arctic Oil Drilling in Alaska
An Overview of Endangered Species Policies and Categories
policy defense.
Evaluation of the Bereavement Risk Index (BRI): a community hospice care protocol.
Shelley and Swinburne's Aesthetic of Melody.


text:
|}
Calea ferată Videle-Giurgiu este o cale ferată secundară în România.

Videle-Giurgiu

redpajama_set_name: RedPajamaWikipedia


To request the immediate termination of payment on a single check to a single payee or if your checks have been lost or stolen please contact your local branch.
You may also request a Stop Payment conveniently through your Online Banking.
Was there another means of payment?
A nominal $35 fee will be automatically deducted from the customer's checking account. A Stop Payment Request order is VOID if the check clears prior to the Stop Payment Request being placed. If the check is presented on the same day as the Stop Payment Request, the Stop Payment Request may not be processed. A Stop Payment Authorization form will be mailed to the account holder immediately by the Bank, it will reflect our understanding of the order. An electronic Stop Payment Request order is effective for 14 calendar days only. A written Stop Payment Request, signed by a depositor, will be effective for 6 months, but may be renewed in writing. (UCC 4-403)The customer agrees to hold the institution harmless for all expenses and costs incurred by the institution for refusing payment of said draft and agrees not to hold the institution liable if payment occurs contrary to the request if same occurs through inadvertence, accident or oversight.


text:
INSIGHTS SUCCESS
Get A Chance To Feature In Magazine By Submitting Your Interview Today!
Facebook Twitter Pinterest Linkedin Instagram
Eric Zi
Venus Medtech Inc. Hangzhou – Global Leader in Transcatheter Therapy Products for Structural Heart Disease
Necessity is the mother of inventions!' Today, this saying fits the healthcare industry more aptly than ever before, as the global healthcare industry continues to demand innovative products that improve treatment and save as many lives as possible.
The drastically changing lifestyle and the rapid pace of life have given rise to various structural heart diseases worldwide. It is known that matters related to heart diseases need to be dealt with delicately and with the best medical therapy available. Venus Medtech (Hangzhou) Inc. came into existence to empower the healthcare industry with superior technology-enabled products for the treatment of structural heart diseases.
Venus Medtech is a leader in transcatheter structural heart valvular therapies in China. Founded in 2009, the company is located in the Hangzhou National High-Tech Industrial Development Zone (Binjiang) and is committed to the development and industrialization of transcatheter therapy products for structural heart disease. Venus is the brainchild of the visionary and expert leader, Eric Zi. As the Executive Director and General Manager of the company, he ensures that the company always keeps innovating and expanding its presence worldwide with superior products.
Without further ado, let's delve into the success story of Venus Medtech:
Comprehensive Solutions for Structural Heart Disease
As China's dominant provider of transcatheter aortic valve replacement (TAVR) devices, Venus Medtech sustained its industry leadership in 2021, covering nearly 70% of implantations in the market.
Four industry-first achievements mark the impressive progress of Venus Medtech:
· The first company to start and complete NMPAregistered (The National Medical Products Administration) clinical studies.
· The first cardiovascular device approved by the NMPA Green Pathway for Innovative Medical Devices
· The first created-in-China heart valve device to conclude First-in-Man clinical use in Europe
· The first company approved to establish a heart valve research institute in China.
Venus Medtech has established comprehensive solutions for structural heart disease, with a complete product pipeline covering all four heart valves, namely TAVR (transcatheter aortic valve replacement), TPVR (transcatheter pulmonic valve replacement), TMVR (transcatheter mitral valve replacement), and TTVR (transcatheter tricuspid valve replacement), as well as hypertrophic cardiomyopathy, hypertensive renal denervation (RDN) therapy, and relevant accessory products.
On December 10, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (SEHK)
with stock code 02500.
Leading Manufacturer of TAVR Devices
Venus Medtech owns the earliest first-generation, and second-generation TAVR products (VenusA-ValveTM and
VenusA-PlusTM) approved for marketing in China. They have been implanted into over 10,000 patients and have
covered 370 hospitals and medical centers nationwide so far. A wealth of clinical follow-up data was gathered from these establishments, sufficiently testifying to their safety and effectiveness. VenusA-ValveTM is currently the only TAVR product with long-term safety verification for more than seven years in China.
As China's dominant provider of transcatheter aortic valve replacement devices, Venus Medtech sustained its industry leadership in 2021, covering nearly 70% (the largest) of the market share. Also, Venus Medtech boasts a best-in-class innovative cardiovascular device marketing team, which has by October, 2022 expanded to 260 members.
Systematic marketing training enabled Venus's marketing team to better inform and assist doctors and patients on the clinical use of the products, ensuring strong support and considerate services.
Spreading Wings Worldwide
Venus Medtech has been expanding its global presence at a robust pace while keeping its leading position in commercialization in China. Europe is the bridgehead of Venus Medtech's international strategy. The TriGUARD3TM cerebral embolic protection (CEP) device, the company's first innovative medical device launched in Europe (March 2020), is widely recognized by clinical experts. Venus Medtech registered RMB10.51 million in overseas revenue in 2021, a marked year-on-year increase of 160.5%, with the sales of TriGUARD3™. And its in-house team developed an innovative TPVR system that obtained CE marking under the Medical Devices Regulation (MDR) on April 8, 2022.
VenusP-ValveTM is the first Chinese-made artificial heart valve approved in Europe; the first self-expanding TPVR product available in the Europe and the first Class III implantable cardiovascular device approved under the new MDR, marking a new milestone in the global presence of China's innovative medical devices. By now, VenusPValveTM has completed the first commercial case in Europe and obtained approval from FDA (Food and Drug Administration) for Compassionate Use. With the approval by China's National Medical Products Administration (NMPA) in July 2022, VenusP-Valve™ became the first self-expanding TPVR product approved in both China and Europe. Moreover, Venus Medtech has built a winning commercialization team for the European market. The company has also engaged quite an amount of marketing veterans as senior managers.
Last but not least, Venus Medtech has attached great importance to intellectual property protection. Leveraging
its strong R&D capability, as of October 2022, a total of over 800 patents and patents under applications, including over 300 authorized invention patents. Its global IP portfolio mainly covers China, the U.S., Europe, Japan, Canada, Russia, India, Brazil, and other countries.
Exclusive and Innovative Solutions Portfolio
Venus Medtech owns a complete product pipeline covering all four heart valves: TAVR, TPVR, TMVR, and TTVR.
TAVR: VenusA-ValveTM, developed by Venus Medtech, is the first NMPA-approved TAVR product and the first TAVR product commercialized in China.
VenusA-PlusTM is the earliest second-generation (retrievable) TAVR product approved for marketing in China.
TMVR & TTVR: Venus Medtech invested in Valgen Medtech in May 2021 to improve its strategic layout in the field of structural heart disease treatment and enhance the product layout in mitral valve repair and tricuspid valve repair. Its DragonFly is the first transfemoral mitral valve TEER product in China, and its DragonRing acts as the first catheter-based transfemoral direct annuloplasty ring system innovated in China that simulates the gold-standard atrioventricular annuloplasty technique from contemporary cardiac surgery.
Cardiovalve: Venus Medtech acquired Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatment company, in January 2022. This acquisition enabled Venus Medtech to become one of the most complete platform companies in the field of mitral regurgitation and tricuspid regurgitation treatment in China. It's noteworthy to mention that Cardiovalve stands as the first privately held company to receive FDA's early feasibility study (EFS) approval for both TR and MR indications.
TPVR: VenusP-ValveTM, Venus Medtech's in-house developed innovative TPVR system, obtains CE marking
under MDR and debuts in Europe as China's first valve product. Following its CE MDR approval, the recent
approval of VenusP-Valve™ in China made it the first selfexpanding TPVR product approved in both China and Europe. It is also the first self-expanding TPVR product available in Europe.
Existing TPVR products in the European market, due to their balloon-expandable design, apply to patients with
particular anatomic structures only and require pre-stenting. Moreover, as these valves come in small diameters, they only work for 15% to 20% of patients. Prior to the certification of VenusP-ValveTM, there was no TPVR product suitable for different anatomical structures and available in such a wide range of specifications.
The Expert Leader
Eric Zi is the Executive Director and General Manager of Venus Medtech. He has over 20 years of R&D and operations experience in the implantable medical devices industry. He always insists on developing unprecedented, ground-breaking technologies in China and beyond. Eric's experience as the main designer of China's firstgeneration PTCA balloon, coronary stent, aortic aneurysm stent, and left atrial appendage occluder gave him a glimpse of the way forward for Chinese medical devices. Later, he developed the first generation of congenital heart disease interventional occluder and inferior vena cava thrombus filter products in China, and successfully introduced them to international markets.
Venus Medtech is Eric's third entrepreneurial venture. "Given my past experience, I know at the very beginning
what kind of company is to be established and the vision ahead (becoming a global leader in structural heart
disease)," he says.
He elaborates further, "I can still recall that my 20 team members and I took every opportunity to study foreign
products. We would calculate the product parameters by merely looking at pictures of various international
exhibitions. I would like to mention that before VenusAValve, there was not even a single China-made TAVR valve. We were brave enough to enter 'no man's land'."
However, the huge gap in technology at home and abroad was what his team had to face in the early stages of his entrepreneurship. Patient screening, BAV(bicuspid aortic valve), severe calcification of Chinese patients, and a small vascular approach posed a great challenge to the company during the initial days. The team took five years (2006–2011) to bring their concept to a real device, and another five years (2012–2017) to put the device into practice. It made continuous improvements and upgrades based on its clinical outcomes.
Eric and his team's hard work finally paid off as the self-developed VenusA-ValveTM was approved by NMPA in 2017, becoming China's first TAVR system. Afterwards, the first TAVR system with a retrievable function in China, VenusA-PlusTM, was approved by NMPA in 2020. VenusPValve™, Venus Medtech's in-house developed innovative TPVR system obtained CE marking under MDR and was approved by NMPA in 2022, making it the first selfexpanding TPVR product approved in both China and Europe.
Eric asserts, "As one of the earliest med-tech moves into transcatheter structural heart valvular therapies in China, we keep creating innovative products with global influence and high clinical value." He was keenly aware of the importance of promoting innovation through international cooperation. Leveraging Eric's experience and interpersonal network, Venus Medtech established a Global Advisory Board to target the international market. The Board members include world-renowned experts specializing in interventional cardiology, namely, Ziyad M. Hijazi, Martin B. Leon, Horst Sievert, and Ron Waksman (in alphabetic order by last name). "With our Global Advisory Board, we are able to connect the world's top doctors and high-tech talents more closely and efficiently. This is critical for our overseas development and commercialization," Eric affirms.
Conquering Challenges
Challenges are unavoidable if a company must keep progressing and living up to market expectations. Eric talks about the present challenges at Venus, saying, "At present, expanding our global presence is a major challenge. Engaging in international business means facing different local laws and regulations as well as different commercial environments."
Taking Europe as the bridgehead of Venus Medtech's international strategy, the company has put two products in Europe: the cerebral embolic protection device TriGUARD3TM, also its first innovative device approved in Europe; and VenusP-ValveTM, the innovative TPVR system, which received CE marking in April 2022. "We've gained rich experience in carrying out clinical trials, registration, and commercialization," Eric points out.
Referring to different quality standards, it would be difficult to establish an integrated system suitable for domestic and international standards. Fortunately, attempts have been made by Venus Medtech. The company has established a quality management system that meets the requirements of GMP of NMPA of the PRC, cGMP of FDA of the U.S., MDR of the EU, BGMP of ANVISA of Brazil, ISO13485, and other regulations and standards. And it carries out quality control in the whole life cycle of products, from R&D to post-marketing sales. This laid a solid foundation for Venus's international strategy.
The Expert Guidance
When Eric was asked what advice he would like to give to healthcare manufacturing industry aspirants and entrepreneurs, he offered rich guidance. He asserts, "As an insider in the med-tech industry for over 20 years, I would say when venturing into the healthcare manufacturing industry, especially the innovative med-tech industry, entrepreneurs should have the mindset to make long-term efforts."
"It may take eight to ten years or even longer for the result to come. Be prepared for this. Difficulties and challenges are all along the way. Giving up is quite easy, right after failure. However, always remember that perseverance does win out."
Scaling Operations in the Near Future
Management affirms that Venus Medtech plans to expand its global presence while retaining its leading position in commercialization in China. In addition to the EU, Venus P-Valve™ was approved by NMPA and became the first self-expanding TPVR product approved in both China and Europe. With plans to launch clinical trials in the US in 2023, Venus Medtech is preparing for its investigational device exemption (IDE) application to the FDA. In May 2022, VenusP-ValveTM has also been approved by the FDA to carry out two cases of compassionate use in the United States.
In Europe, TriGUARD3™ (Venus's cerebral embolic protection device) is expected to continue to gain market share from Sentinel (another cerebral embolic protection device from Boston Scientific) in the coming years.
On the clinical side:
Venus Medtech's Liwen RF™ radiofrequency ablation system for treating hypertrophic cardiomyopathy (HCM) is going to obtain approval to start a clinical trial in Europe very soon.
The company's Cardiovalve™ (TMVR and TTVR systems) will be speeding up its clinical trials in Europe, North America, and China. "Moving forward, Venus Medtech will focus on new materials, bionics, image fusion techniques, and digital sensing for continuous upgrades and innovation to meet the needs of doctors and patients worldwide," Eric reveals.
Further, he says, "As a leading company in the field of the heart valve, we aim to motivate and inspire innovators in China's healthcare sector with our path to development.
Innovation drives the future."
"At Venus Medtech, we will continue our efforts to develop and commercialize novel structural heart devices,
supporting China's rise as an innovation powerhouse and contributing to the well-being of global communities," he concludes.
Venus Medtech has received a wealth of awards at national, provincial and municipal levels as follows.
https://www.venusmedtech.com/index.php/about/ABOUTUS-Venus-Medtech.
OTCXN: Using Blockchain to Solve the Hardest Problems
AMS Fulfillment: An Operational Arm that Transitions Business to Brand Success
VeriQloud: Offering Applications and Software for Quantum Networks
Swift Deposits & Withdrawals: 6 Best Payment Methods for German Online Casinos
The 10 Most Innovative Pharma and Biotech Solution Providers, 2023 January2023
Anju Software: Delivering Adaptive Life Sciences Software
BuzzFeed Stock Increases 150% as it Plans to Use AI to Create Content
Chidiebere Moses Ogbodo – Editor-in-Chief
Facebook-f Twitter Pinterest Linkedin Instagram
Insights Success is an archway that caters to Entrepreneurs' quench of technology and business updates which are currently ruling the business world.
We are ceaselessly proving the best platform for leading companies, which aids indefinite progress while creating meaningful learning experiences for the visitors and invaluable brand awareness for the clients.
© Copyright 2022, InsightsSuccess | All Rights Reserved.


Apologies for a lack of a match report for last week's game, I was away and had handed duties over to my esteemed colleague JB. I should imagine that his reluctance to write the report may have something to do with him being bowled by Winchelsea's star player, who was a 12 year old girl.
By all accounts it sounded like a cracking game of cricket, with Winchelsea nicking it in the last over, after chasing down Newenden's 228.
Normal service was resumed yesterday as Newenden put Sissinghurst to the sword. There had been quite a build up to the game as several of our 1st XI play for Sissinghurst on a Saturday, so there was always going to be an edge to the match.
After winning the toss,Newenden stuck with the formula that has suited them all season, and batted first. Harker carried on his recent good form, smashing a quickfire 25, which set the tone for the innings.There were decent contributions from all the top order, but with no one going onto to make a significant score. A healthy run rate was maitained, as the batsmen helped themselves to the buffet bowling of Sissinghurst. Father and Son, Ian and George Jones, batting for the first time together, saw us through to a daunting 290 off our 40 overs.
Sissinghurst came out of the traps fast, as they had to maintain an oppressive run rate to stay in the game, and all credit to them as they were up with it for the first 15 overs. Harry Bradney bowled a tidy spell from the top end, where he picked up the well deserved wicket of the opening bat. With Karl Rummery taking the gloves for this game, Bradney's opening partner was Garry Smith, who Sissinghurst's overseas player took a particular liking to, but as Garry always does, he picked up a wicket, which takes his tally up to 13 for the season. As things were starting to look a little concerning, O'Brien came on at the Pavillion end, and swung the game firmly back in our favour. Bowling 5 overs of top quality spin, he picked up 3-5, including the Sissingurst dangerman Wundenberg, who was caught by a fantastic catch in the slips by debutant Harry Scowers.
Sissinghurst rallied, but were burdened by the scoreboard pressure, and were finally all out for 213 without seeing out their overs.Special mention must go to Newenden youngsters, Alex Bartleet and George Jones, who bowled two great spells. Bartleet finishing up with 0-27 off his 7 overs, and Jones with 2-16 off his 4 over spell. The future looks bright for Newenden.
We have another big game next week, as we travel down to Crowhurst Park, but we are high on confidence and expect to be a match for any side.